Rebecca Robbins

1 month ago | nytimes.com | Rebecca Robbins |Margot Sanger-Katz

The president announced an executive order aimed at lowering U.S. drug costs, revisiting an idea that was blocked in court during his first term. President Trump will sign an executive order on Monday aimed at lowering some drug prices in the United States by aligning them with what other wealthy countries pay, he said on Truth Social on Sunday evening. The proposal he described, which alone cannot shift federal policy, is what he calls a "most favored nation" pricing model.

1 month ago | nytimes.com | Rebecca Robbins |Reed Abelson

CVS Caremark decided to stop offering Zepbound in favor of Wegovy for weight loss. It's the latest example of limits imposed by insurance that disrupt treatments for patients. Tens of thousands of Americans will soon be forced by their heath insurance to switch from one popular obesity drug to another that produces less weight loss.

2 months ago | rethinking65.com | Rebecca Robbins

Hundreds of thousands of Americans stand to soon lose their access to cheaper weight-loss drugs, with a federal crackdown on copycat versions threatening to disrupt treatment and raise costs. The Food and Drug Administration has ordered producers and sellers of the less expensive products to wind down operations in the coming weeks now that it has declared there are no longer shortages of the blockbuster drugs Wegovy and Zepbound.

2 months ago | nytimes.com | Teddy Rosenbluth |Rebecca Robbins

An interim U.S. attorney is demanding information about the selection of research articles and the role of N.I.H. Experts worry this will have a chilling effect on publications. A federal prosecutor has sent letters to at least three medical journals accusing them of political bias and asking a series of probing questions suggesting that the journals mislead readers, suppress opposing viewpoints and are inappropriately swayed by their funders.

2 months ago | nytimes.com | Rebecca Robbins |Gina Kolata

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. Encouraging clinical trial results announced on Thursday stand to open up a huge market for a convenient daily pill to treat obesity and diabetes. The experimental drug, developed by Eli Lilly and known as orforglipron, is a type of medication known as a GLP-1.